Search results
Guselkumab Provides Long-Term Relief From PsA Symptoms
Medscape· 7 days agoGuselkumab improved joint swelling, spinal pain, skin symptoms, and overall disease activity in a...
Stelara biosimilar from Alvotech, Teva approved by FDA
BioPharma Dive via Yahoo Finance· 7 days agoThe FDA cleared Selarsdi for treatment of moderate to severe plaque psoriasis and active psoriatic ...
FDA Approves Second Ustekinumab Biosimilar
Medscape· 7 days agoThe biosimilar is expected to be marketed in the United States on or after February 21, 2025.
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 11 hours agoSource: Takeda Pharmaceutical. Conclusion Takeda is one of the leaders in the global gastrointestinal and cancer therapeutics markets, which is...
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant...
NBC 17 Raleigh· 6 days ago− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen ...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening...
Morningstar· 2 days agoAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming ...
Cantargia Publishes New Data on the CAN10 Antibody, Detailing its Interaction with IL1RAP and...
Digital Journal· 6 days agoThe CAN10 surrogate also inhibited disease development in models of systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis and peritonitis.
Johnson & Johnson (NYSE:JNJ) Issues FY24 Earnings Guidance
ETF DAILY NEWS· 5 days agoJohnson & Johnson (NYSE:JNJ – Get Free Report) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $10.57-10.72 for the period, compared to the consensus EPS ...
Johnson & Johnson (NYSE:JNJ) Position Lowered by Lakeside Advisors INC.
ETF DAILY NEWS· 16 hours agoLakeside Advisors INC. trimmed its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities ...
Johnson & Johnson Sees Unusually High Options Volume (NYSE:JNJ)
ETF DAILY NEWS· 23 hours agoJohnson & Johnson (NYSE:JNJ – Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 45,802 call options on the company. Raymond James ...
